Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Current considerations for the management of musculoskeletal pain in Asian countries: A special focus on cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs
Authors: Chaudakshetrin Pongparadee
Ester Penserga
David Jeng Shiang Lee
Shun le Chen
Ranjit Singh Gill
Abdulbar Hamid
Witsanu Kumthornthip
Yi Liu
Lucus Meliala
H. Jusuf Misbach
Kian Hian Tan
Swan Sim Yeap
Sow Nam Yeo
Hsiao Yi Lin
Mahidol University
University of the Philippines College of Medicine
MSD Taiwan
Shanghai Second Medical University
Kuala Lumpur Sports Medicine Centre
Universitas Indonesia
West China Hospital of Sichuan University
Faculty of Medicine University of Gadjah Mada
Singapore General Hospital
Sime Darby Medical Centre
Mount Elizabeth Medical Centre
National Yang-Ming University Taiwan
Keywords: Medicine
Issue Date: 1-Aug-2012
Citation: International Journal of Rheumatic Diseases. Vol.15, No.4 (2012), 341-347
Abstract: Chronic pain is a complex problem that eludes precise definition and can be clinically difficult to diagnose and challenging to treat. In the Asia-Pacific region, prevalence estimates that chronic pain ranges from 12% to 45% of the population, with musculoskeletal, rheumatic or osteoarthritis pain making up the majority of the disease burden. Implementation of current management guidelines into routine clinical practice has been challenging and as a result, patients with musculoskeletal pain are often poorly managed. For these reasons, a multidisciplinary Chronic Pain Advisory Board of leading physicians from various Asian countries was convened to explore ways to improve treatment and compliance, especially among patients with osteoarthritis and rheumatoid arthritis. We have identified a number of unmet therapeutic needs and prioritized initiatives with the potential to contribute toward a more integrated approach to chronic pain management. Key priorities included using evidence-based interventions as recommended by current guidelines, particularly those aspects pertinent to addressing treatment priorities in Asia (e.g., patient compliance), and the incorporation of cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs into the management algorithms for osteoarthritis and rheumatoid arthritis. Treatment must be individualized for each patient based on efficacy, side-effect profile and drug accessibility. Further studies are required to examine head-to-head comparisons among analgesics, combinations of analgesics and long-term efficacy outcomes. Our increasing understanding of the problem combined with the promise of new therapy options offers hope for improved management of musculoskeletal pain in Asian countries. © 2012 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.
ISSN: 1756185X
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.